Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012;17(9):1129-32.
doi: 10.1634/theoncologist.2012-0209. Epub 2012 Aug 22.

Randomization and statistical power: paramount in trial reproducibility (even for rare cancers)

Laurence H Baker  1 , John J Crowley, Robert G Maki
Affiliations
Comment

Randomization and statistical power: paramount in trial reproducibility (even for rare cancers)

Laurence H Baker et al. Oncologist. 2012.

Abstract

This article comments on the importance of randomization and statistical power in clinical trials.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Laurence H. Baker: BioMed Valley, CytRx (C/A); Robert G. Maki: Eli Lilly (C/A, RF), Sanofi-Aventis (C/A). The other author indicated no financial relationships.

Comment on

References

    1. Brumfiel G. Physicists declare victory in Higgs hunt. [Accessed August 3, 2012]. Available at http://www.nature.com/news/physicists-declare-victory-in-higgs-hunt-1.10940.
    1. Vogelzang NJ, Benowitz SI, Adams S, et al. Clinical cancer advances 2011: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012;30:88–109. - PubMed
    1. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483:531–533. - PubMed
    1. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas : A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French sarcoma group study (TAXOGEM study) The Oncologist. 2012;17:1213–1220. - PMC - PubMed
    1. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol. 2002;20:2824–2831. - PubMed